Few & Far Between: Conversations from the Front Lines of Drug Development

How do you turn back the epigenetic clock for humans and their animal companions?  Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming. Listen in to the latest episode of the Few & Far Between podcast today!  

Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases. Host Chris O'Brien welcomes Jonathan Rigby, Chairman and CEO at Sernova, to the podcast. Listen in as we spotlight Jonathan's 30-year industry journey, the development of implantable bio-hybrid organs, and how to plan for your first 30 days in a new biotech role. Tune in today!

Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you early access to information on emerging trends in clinical trials.   On today's episode, host Chris O'Brien welcomes Eileen Faucher. Eileen is the Principal and Founder of Brass Tacks Health, a company that provides insights that biotechs need to drive clinically-meaningful therapies. Listen in to get the ROI on competitive intelligence, concise communications, and helping patients find relevant clinical trials. Thanks for listening!

"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes John Celebi to the pocast. Be sure to tune in for insights into assembling a core management team and how to build openness and inclusivity into biotech company culture. Thank's for listening!

In this discussion, Ben Olds, an Executive Coach and Managing Partner at Haven Human Asset Ventures, and Amy Fenollosa, also a Managing Partner, delve into the complexities of leadership in biotech. They emphasize the necessity of nurturing an intentional company culture that encourages innovation and open communication. The duo discusses fostering psychological safety, the importance of constructive feedback, and the value of embracing intelligent failure in leadership. They also touch on personalized management strategies that respect individual team members’ needs.

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today!

"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not destroyed during nebulization." - Dr. Carsten Rudolph, CEO and Managing Director at Ethris Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Dr. Carsten Rudolph, as they discuss the current state and bright future of nasal vaccine technology. Tune in today!

"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity. Tune in today!

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon Therapeutics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financing in the biotech world. Tune in today! 

“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they discuss technological innovations in guiding individualized patient treatments. Tune in today!